Actinium Pharmaceuticals, Inc. — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. This is an annual filing, not a standalone Q4 report. Actinium is a clinical-stage biotechnology company developing targeted radioimmunotherapies; it had no commercial product sales or revenue.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $13.31 million | $12.27 million |
| General and administrative expense | $11.46 million | $10.18 million |
| Operating loss | $24.83 million | $22.48 million |
| Net loss | $21.03 million | $24.69 million |
| Net loss per share, basic and diluted | $0.55 | $0.90 |
| Cash used in operating activities | $18.54 million | $14.35 million |
| Cash and cash equivalents at year-end | $25.64 million | $6.71 million |
| Total assets | $26.59 million | $7.57 million |
| Total liabilities | $4.61 million | $9.49 million |
| Stockholders’ equity (deficit) | $21.97 million | $(1.92) million |
Year-end current assets were $26.48 million and current liabilities were $4.61 million. Current liabilities included $265,695 of notes payable, described as insurance-premium financing, and $2.85 million of derivative liabilities; the filing reports no long-term liabilities. Cash flow from financing was $37.53 million, principally from stock offerings. The filing states the company expected to need approximately $20 million over the next 12 months and believed available working capital would fund operations for that period.
No meaningful revenue margin was reported because there were no sales. Operating cash use increased year over year. Net loss improved despite a higher operating loss, mainly because of a $3.81 million noncash gain from revaluing derivative warrant liabilities; stock-based compensation was $7.06 million.
Material changes versus prior year
- Cash increased by $18.94 million, primarily reflecting $37.64 million of net stock-offering proceeds; common shares outstanding rose from 29.97 million to 44.07 million during 2015.
- Operating cash use increased by $4.20 million, and operating loss grew by $2.35 million as development and administrative spending rose.
- Net loss narrowed by $3.66 million, largely because the derivative-liability remeasurement moved from a $2.21 million loss in 2014 to a $3.81 million gain in 2015.
- Research and development costs rose approximately $1.0 million; general and administrative costs rose approximately $1.3 million.
Business, outlook, risks and unusual items
- Iomab-B: The FDA cleared the IND in December 2015 for a planned pivotal Phase 3 trial in relapsed or refractory AML patients aged 55 and older. The proposed randomized, controlled study has 150 patients, with durable complete remission as the primary endpoint and one-year overall survival as a secondary endpoint. Management expected enrollment to begin in the first half of 2016, subject to trial execution and funding. The filing estimated direct trial-completion costs of approximately $25 million and anticipated completion in 2018. A subsequent February 2016 agreement with Medpace estimated CRO fees of $6.6 million.
- Actimab-A: The company was conducting a multicenter Phase 1/2 trial in newly diagnosed AML patients over age 60. The filing describes dose-related prolonged bone-marrow suppression at higher doses, prompting dose reductions; clinical efficacy and safety remain unproven.
- Funding and dilution: The company has accumulated losses of $112.2 million, expects continuing losses, and has no recurring revenue. It may need further financing or partnerships; additional equity issuance could dilute shareholders. Management said current cash was sufficient for 12 months, but not for full development and commercialization.
- Development and supply risks: Product candidates require clinical and regulatory success and third-party manufacturing. Actimab-A depends on limited Ac-225 supply from ORNL under a contract running through 2016, subject to renewal. The filing also notes Iomab-B lacks patent protection, relying instead on trade secrets and potential regulatory exclusivity.
- Other material exposure: Licensing agreements may require future milestone payments and royalties, including AbbVie royalties of 12% of net sales and MSKCC and FHCRC royalties of 2% each, subject to their respective terms. Derivative warrant fair values are sensitive to stock-price and valuation assumptions.
- Governance and audit: Management and the auditor reported effective internal control over financial reporting, and the auditor issued an unqualified opinion on the financial statements. The filing reports no material legal proceedings or off-balance-sheet arrangements.
Investor facts to verify
- Whether Iomab-B Phase 3 enrollment began as planned, and subsequent progress against its endpoints, timeline and financing requirements.
- Cash runway and operating burn after year-end, including the cost of the Phase 3 trial and any additional equity issuance or dilution.
- Actimab-A trial updates, including dose-limiting toxicity, dose selection and evidence of clinical benefit.
- Renewal and adequacy of the ORNL Ac-225 supply contract and readiness of alternative commercial-scale supply.
- License economics, Iomab-B’s lack of patent coverage, and the potential impact of derivative warrant revaluations.
- The auditor’s internal-control report contains an apparent date inconsistency: its opinion paragraph refers to effectiveness as of December 31, 2014, while the report and management assessment address December 31, 2015.